RT Journal Article
SR Electronic
T1 T cell and antibody functional correlates of severe COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.25.20235150
DO 10.1101/2020.11.25.20235150
A1 Yu, Krystle K.Q.
A1 Fischinger, Stephanie
A1 Smith, Malisa T.
A1 Atyeo, Caroline
A1 Cizmeci, Deniz
A1 Wolf, Caitlin R.
A1 Layton, Erik D.
A1 Logue, Jennifer K.
A1 Aguilar, Melissa S.
A1 Shuey, Kiel
A1 Loos, Carolin
A1 Yu, Jingyou
A1 Franko, Nicholas
A1 Choi, Robert Y.
A1 Wald, Anna
A1 Barouch, Dan H.
A1 Koelle, David M.
A1 Lauffenburger, Douglas
A1 Chu, Helen Y.
A1 Alter, Galit
A1 Seshadri, Chetan
YR 2020
UL http://medrxiv.org/content/early/2020/11/30/2020.11.25.20235150.abstract
AB Comorbid medical illnesses, such as obesity and diabetes, are associated with more severe COVID-19, hospitalization, and death. However, the role of the immune system in mediating these clinical outcomes has not been determined. We used multi-parameter flow cytometry and systems serology to comprehensively profile the functions of T cells and antibodies targeting spike, nucleocapsid, and envelope proteins in a convalescent cohort of COVID-19 subjects who were either hospitalized (n=20) or not hospitalized (n=40). To avoid confounding, subjects were matched by age, sex, ethnicity, and date of symptom onset. Surprisingly, we found that the magnitude and functional breadth of virus-specific CD4 T cell and antibody responses were consistently higher among hospitalized subjects, particularly those with medical comorbidities. However, an integrated analysis identified more coordination between polyfunctional CD4 T-cells and antibodies targeting the S1 domain of spike among subjects that were not hospitalized. These data reveal a functionally diverse and coordinated response between T cells and antibodies targeting SARS-CoV-2 which is reduced in the presence of comorbid illnesses that are known risk factors for severe COVID-19. Our data suggest that isolated measurements of the magnitudes of spike-specific immune responses are likely insufficient to anticipate vaccine efficacy in high-risk populations.Competing Interest StatementDr. Chu reports grants from Bill and Melinda Gates Foundation, and NIH during the conduct of the study; consulting with Merck and the Bill & Melinda Gates Foundation, grants from Sanofi Pasteur and Gates Ventures outside the submitted work, and non-financial support from Cepheid and Ellume. Dr. Wald reports grants from the NIH, Sanofi-Pasteur, GlaxoSmithKline, and consulting with Aicuris, Merck, and X-Vax outside the submitted work. Dr. Koelle reports consulting with Curevo, MaxHealth, and Gilead, and grants from Sensei and Sanofi Pasteur outside the submitted work. Dr. Barouch reports no financial conflicts of interest with the work presented here.Funding StatementWe acknowledge support from the Ragon Institute of MGH, MIT, the Massachusetts Consortium on Pathogen Readiness (MassCPR to G.A.), the Bill & Melinda Gates Foundation (235730 to G.A. and INV-016575 to H.Y.C), NIAID (U19 AI35995 to G.A., R01-AI125189 to C.S., and Contract HHSN272201400049C to D.M.K.), the Doris Duke Charitable Foundation (20160103 to C.S.), and the U.S. Centers for Disease Control and Prevention (CK000490 to G.A.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The studies were approved by the University of Washington Human Subjects Institutional Review Board. The IRB study ID is STUDY00000959.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available upon request.